BR0011880A - Method for the treatment of co-morbid conditions associated with obesity, compound, product, use of a compound, and pharmaceutical composition - Google Patents

Method for the treatment of co-morbid conditions associated with obesity, compound, product, use of a compound, and pharmaceutical composition

Info

Publication number
BR0011880A
BR0011880A BR0011880-0A BR0011880A BR0011880A BR 0011880 A BR0011880 A BR 0011880A BR 0011880 A BR0011880 A BR 0011880A BR 0011880 A BR0011880 A BR 0011880A
Authority
BR
Brazil
Prior art keywords
compound
treatment
obesity
conditions associated
pharmaceutical composition
Prior art date
Application number
BR0011880-0A
Other languages
Portuguese (pt)
Inventor
David John Heal
Original Assignee
Knoll Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Gmbh filed Critical Knoll Gmbh
Publication of BR0011880A publication Critical patent/BR0011880A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"MéTODO PARA O TRATAMENTO DE CONDIçõES CO-MóRBIDAS ASSOCIADAS COM OBESIDADE, COMPOSTO , PRODUTO, USO DE UM COMPOSTO, E, COMPOSIçãO FARMACêUTICA". Método para o tratamento de condições co-mórbidas associadas com obesidade em humanos necessitados de tal tratamento que compreende administração ao humano de quantidade terapeuticamente efetiva do composto de fórmula (I): que inclui enanciómeros e sais farmaceuticamente aceitáveis dos mesmos, em que R~ 1~ e R~ 2~ são independentemente H ou metila, e quantidade terapeuticamente efetiva do composto de fórmula (II) em que o composto de fórmula (I) e o composto de fórmula (II): são administrados simultaneamente, separadamente ou seq³encialmente."METHOD FOR THE TREATMENT OF COMBOSIBLE CONDITIONS ASSOCIATED WITH OBESITY, COMPOUND, PRODUCT, USE OF A COMPOUND, AND PHARMACEUTICAL COMPOSITION". Method for the treatment of co-morbid conditions associated with obesity in humans in need of such treatment which comprises administering to the human a therapeutically effective amount of the compound of formula (I): which includes enantiomers and pharmaceutically acceptable salts thereof, where R ~ 1 ~ and R ~ 2 ~ are independently H or methyl, and therapeutically effective amount of the compound of formula (II) wherein the compound of formula (I) and the compound of formula (II): are administered simultaneously, separately or sequentially.

BR0011880-0A 1999-06-24 2000-06-16 Method for the treatment of co-morbid conditions associated with obesity, compound, product, use of a compound, and pharmaceutical composition BR0011880A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9914744.9A GB9914744D0 (en) 1999-06-24 1999-06-24 Therapeutic agents
PCT/EP2000/005542 WO2001000205A1 (en) 1999-06-24 2000-06-16 Pharmaceutical composition containing sibutramine and orlistat

Publications (1)

Publication Number Publication Date
BR0011880A true BR0011880A (en) 2002-03-19

Family

ID=10855955

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0011880-0A BR0011880A (en) 1999-06-24 2000-06-16 Method for the treatment of co-morbid conditions associated with obesity, compound, product, use of a compound, and pharmaceutical composition

Country Status (21)

Country Link
EP (1) EP1187606A1 (en)
JP (1) JP2003503349A (en)
KR (1) KR20020015357A (en)
CN (1) CN1358092A (en)
AU (1) AU5533200A (en)
BG (1) BG106180A (en)
BR (1) BR0011880A (en)
CA (1) CA2375972A1 (en)
CZ (1) CZ20014613A3 (en)
GB (1) GB9914744D0 (en)
HK (1) HK1049278A1 (en)
HU (1) HUP0201878A3 (en)
IL (1) IL147079A0 (en)
MX (1) MXPA01012936A (en)
NO (1) NO20016224L (en)
PL (1) PL352402A1 (en)
RU (1) RU2229289C2 (en)
SK (1) SK18242001A3 (en)
TR (1) TR200103699T2 (en)
WO (1) WO2001000205A1 (en)
ZA (1) ZA200109989B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696495B2 (en) * 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US20040214804A1 (en) * 2003-04-25 2004-10-28 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an anti-obesity agent
CA2585175A1 (en) 2004-10-25 2006-05-04 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions
JP2010503709A (en) * 2006-09-15 2010-02-04 レビバ ファーマシューティカルズ，インコーポレーテッド Synthesis, methods of use and compositions of cycloalkylmethylamines
BRPI0716002A2 (en) * 2006-11-22 2013-07-30 Sk Chemicals Co Ltd Inclusion complex, process of preparation of an inclusion complex and composition of treatment and prevention of hypochondria and obesity
CN101890017A (en) * 2009-05-22 2010-11-24 北京奥萨医药研究中心有限公司 Medicament composition containing sibutramine and stanin fat-reducing medicament and application thereof
WO2012003501A2 (en) 2010-07-02 2012-01-05 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
MX336980B (en) * 2010-12-21 2016-02-09 Senosiain S A De C V Lab Combination and composition for treating obesity.
US9238625B2 (en) 2011-12-30 2016-01-19 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9727131D0 (en) * 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents

Also Published As

Publication number Publication date
PL352402A1 (en) 2003-08-25
HUP0201878A3 (en) 2005-04-28
RU2229289C2 (en) 2004-05-27
CZ20014613A3 (en) 2003-04-16
NO20016224D0 (en) 2001-12-19
ZA200109989B (en) 2003-02-26
AU5533200A (en) 2001-01-31
HK1049278A1 (en) 2003-05-09
NO20016224L (en) 2002-02-12
TR200103699T2 (en) 2002-04-22
IL147079A0 (en) 2002-08-14
MXPA01012936A (en) 2004-04-21
GB9914744D0 (en) 1999-08-25
SK18242001A3 (en) 2003-02-04
WO2001000205A1 (en) 2001-01-04
EP1187606A1 (en) 2002-03-20
JP2003503349A (en) 2003-01-28
BG106180A (en) 2002-08-30
KR20020015357A (en) 2002-02-27
CN1358092A (en) 2002-07-10
HUP0201878A2 (en) 2003-08-28
CA2375972A1 (en) 2001-01-04

Similar Documents

Publication Publication Date Title
BR0315337A (en) Compound, pharmaceutical formulation, and method for treating cancer
BR0012590A (en) Compound, process for its preparation, pharmaceutical formulation, use of a compound, and, methods for treatment or prophylaxis of pain or discomfort, and for treatment or prophylaxis of neuropathic or central pain
GEP20043324B (en) Purine Derivatives
BR0000003A (en) Azalides and methods of preparing them
CY1107850T1 (en) THIADIAZYLOPIPERAZINE PRODUCT WITH USE IN APTROPIC OR IN ACTION AGAINST ALGUES
TR199801180T2 (en) New compounds with analgesic effect.
BR0113496A (en) A compound or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, use thereof, method for producing a cell cycle inhibitory effect (anti-cell proliferation) in a warm-blooded animal, and pharmaceutical composition.
MY132705A (en) Novel compounds with analgesic effect
BR0212042A (en) Compound, pharmaceutical composition, method of treating or preventing disease, and use of a compound
CA2274074A1 (en) Novel compounds with analgesic effect
DK0503440T3 (en) Sumatriptan-containing medicines
GEP20002298B (en) Benzimidazole Derivatives, Method of Their Production, Pharmaceutical Composition Containing the Same and Method for Its Treatment
BRPI0415953A (en) oral controlled release dosage formulation, method of treating a disorder, set of controlled release dosage forms and method for administering the formulation
BR0010938A (en) 13-Methyl erythromycin derivatives
SE9900961D0 (en) Novel compounds
BR9814498A (en) Process for the treatment of obesity in a human requiring such treatment, compound, use of the same, product, and pharmaceutical composition
BR9813319A (en) Compound, pharmaceutical composition for treating bacterial infections, and processes for treating bacterial infections and for preparing a compound
BR9915480A (en) Azalides of 13 members and their use as antibiotic agents
BR0011880A (en) Method for the treatment of co-morbid conditions associated with obesity, compound, product, use of a compound, and pharmaceutical composition
BR0007452A (en) Use of melagatran or a pharmaceutically acceptable derivative or prodrug thereof, method of treating inflammation, and, pharmaceutical formulation for use in treating inflammation
GEP20043227B (en) 5HT1 Antagonists for Antidepressant Therapy
BR0011884A (en) Method of treating obesity and comorbid conditions in a human in need of such treatment, compound of formula i, product containing compound of formula i, use of compound of formula i, and pharmaceutical composition
TR200103144T2 (en) New compounds
GEP20043231B (en) Resorcinol Composition
AP9801235A0 (en) Erythromycin derivatives.

Legal Events

Date Code Title Description
PC Transfer

Owner name: ABBOTT GMBH & CO. KG (DE)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled
B25A Requested transfer of rights approved

Free format text: ABBOTT GMBH (DE)

B25D Requested change of name of applicant approved
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008.